We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Under the deal, Lilly will foot the costs of global commercialisation for the therapy, R552, and Rigel will have the right to co-sell the treatment in the US.